|By PR Newswire||
|March 24, 2014 07:01 PM EDT||
DUBLIN, March 24, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/zkjlpz/investigation) has announced the addition of the "Investigation Report on China Atorvastatin Market, 2009-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The prevalence rate of abnormal blood lipid in China is lower than that in most developed countries, but the average serum TC level of Chinese people is upgrading for the economic development and lifestyle change. Meanwhile, diabetes and metabolic syndromes are very common in China.
According to statistics, the prevalence rate of abnormal blood lipid is above 20% in the group aged at 18 or above. The total number of patients exceeds 200 million.
Blood lipid-lowering drugs performs better than the overall drug market and cardiovascular system drugs. The expanding rate of blood lipid-lowering drugs is obviously higher than that of cardiovascular system drugs and the proportion in the cardiovascular system drug market is increasing.
Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It works by inhibiting HMG-CoA reductase. In November 2011, Pfizer lost the patent protection in the USA. In May 2012, Pfizer lost the patent protection in the U.K. either. Liptor is the most popular drug of Pfizer with the accumulated sales value over USD 100 billion. It is the first drug with sales value breaking USD 100 billion in the history.
There are many enterprises producing APIs and finished products of atorvastatin. The market share of finished products is mainly occupied by Pfizer, which is above 80% by sales value every year. According to CRI's investigation, the CAGR of atorvastatin in China sample hospital market is above 40% during 2005-2013.
According to clinic research, atorvastatin has certain curative effects on osteoporosis, Alzheimer's disease, heart disease, organ transplantation, stroke and diabetes.
Key Topics Covered:
1 Relevant Concepts of Atorvastatin
2 Market Overview of Atorvastatin in China
3 Investigation on Sales Value of Atorvastatin in China, 2009-2013
4 Investigation on Market Share of Major Atorvastatin Manufacturers in China, 2009-2013
5 Investigation on Market Size of Atorvastatin by Dosage Form in China, 2009-2013
6 Reference Price of Atorvastatin in Hospital Market in China, 2013
7 Analysis on Major Atorvastatin Manufacturers in China, 2009-2013
8 Prospect of China Atorvastatin Market, 2014-2018
- Beijing Jialin Pharmaceutical Co., Ltd.
- Godecke (GE)
- Henan Topfond Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/zkjlpz/investigation
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
Oct. 27, 2016 08:45 AM EDT Reads: 11,583
Oct. 27, 2016 08:15 AM EDT Reads: 469
Oct. 27, 2016 07:45 AM EDT Reads: 491
Oct. 27, 2016 07:30 AM EDT Reads: 1,930
Oct. 27, 2016 07:30 AM EDT Reads: 1,609
Oct. 27, 2016 07:00 AM EDT Reads: 4,933
Oct. 27, 2016 07:00 AM EDT Reads: 5,012
Oct. 27, 2016 06:45 AM EDT Reads: 1,090
Oct. 27, 2016 06:45 AM EDT Reads: 1,061
Oct. 27, 2016 06:00 AM EDT Reads: 1,035
Oct. 27, 2016 05:45 AM EDT Reads: 1,264
Oct. 27, 2016 05:30 AM EDT Reads: 1,216
Oct. 27, 2016 05:15 AM EDT Reads: 1,140
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Oct. 27, 2016 05:15 AM EDT Reads: 990
The Internet of Things (IoT), in all its myriad manifestations, has great potential. Much of that potential comes from the evolving data management and analytic (DMA) technologies and processes that allow us to gain insight from all of the IoT data that can be generated and gathered. This potential may never be met as those data sets are tied to specific industry verticals and single markets, with no clear way to use IoT data and sensor analytics to fulfill the hype being given the IoT today.
Oct. 27, 2016 04:45 AM EDT Reads: 2,880